MedTrace Logo

Response of FeNO, Small Airway Dysfunction and Lung Heterogeneity to 2-week Montelukast Treatment in Asthmatic Children.

NCT01581710 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-04-12

Study results available
· View outcomes & findings →

Summary

This study aims to identify markers to prove rapid improvement of lung function, airway inflammation and bronchodilator response after 2-week LTRA administration.

Conditions

  • Mild Persistent Asthma

Interventions

DRUG

Montelukast to placebo

Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks

DRUG

Placebo to montelukast

Subjects will receive matching placebo. Each treatment period consists of 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Man Yong Han · specify Unaffiliated

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
3 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2015-09-30
Completion
2015-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01581710 on ClinicalTrials.gov